Hey there, it’s Vadim 👋

Is it just me or does mid-August show no signs of slowing down? 😮‍💨

There are happy hours, virtual meets, and I feel like if I blink, I miss 5 new headlines.

I’m definitely not complaining (it’s been great having a full social calendar), but if this is setting the pace for the rest of the year, then I feel we should brace ourselves :)

Which is why today I’d like to pick up where we left off last week - gauging the quality, and quantity of your investors.

As a refresher, last week we talked about the five ways your investor list may be lying to you - ways that funds on your list were never the ones that were going to write you a check, no matter how polished your deck was.

That was the quality side of the list.

Today, I’d like to talk about quantity.

After all, if you’re after quality investors (as you should be), how many “good” investors are genuinely out there? And how should you go about sourcing your list to make sure it survives contact with reality when you actually run your fundraise?

That’s what we’ll dig into today.

🧭 Here’s what we’ll cover:

  • Why a “good” investor list can still leave you stuck

  • The real, evidence-backed number of meetings it takes to close a seed round

  • Why a 40-50 name list gives you zero margin for normal attrition

  • Five places to find investors most founders overlook

  • Why your list needs to keep growing even after outreach starts

  • And more!

Let's dive in!

FOUNDER STORY

The “Catch-22” of a well-sourced list

Right names, wrong size

If we’ve ever spoken in person, you probably heard me talk about this challenge.

A founder spends weeks building their investor list before reaching out to anyone. This isn’t a spray-and-pray spreadsheet - they have 38 names they actually researched, and the names make sense for their company based on stage, modality, and check size.

Eight weeks later, they had 4 first meetings, which is honestly a great ratio based on my experience.

But two of the funds turn out to have little capital left for new investments. One likes the science but won’t invest until someone else leads the round. Another takes the meeting and then disappears after the follow-up.

“Biotech funding has clearly dried up”, they tell me, after those four meetings.

And of course - yes, biotech funding is tough. And perhaps there were real challenges with their pitch deck or their story.

But the bigger challenge in situations like these is that the founder built a good list without leaving themselves much room for normal fundraising attrition.

Some investors won’t respond. Others will turn out to be less active than they appear. Some will have a conflict, need a lead, or simply decide the company isn’t for them.

In the land of fundraising, that’s just another Tuesday :)

And when you’re starting with 38 names, it only takes a handful of those perfectly normal outcomes before a carefully researched list turns into a very thin pipeline.

Let’s look at how we can avoid this 👇

FRAMEWORK

The attrition budget

If you’ve been reading Bio Founder GPS for a while, you already know the rough shape of a fundraising funnel:

Contacts turn into replies, replies turn into first meetings, first meetings turn into engaged processes, and if enough of those are run successfully, a term sheet (or multiple) come as a result.

But to lay the groundwork for today, I’d like to anchor us on one number that often gets overlooked in fundraising conversations: how many distinct investors you actually need at the end of your funnel, not at the beginning.

From my own experience and work with founders, a seed round typically involves real engagement with somewhere around 30 to 50 distinct investors before a term sheet appears.

Back in 2020, DocSend ran a study comparing founders who successfully closed their round in 2015 and in 2019. In both years, founders who closed averaged 40 investor meetings, even as the number of investors they had to contact to reach those meetings climbed from an average of 58 in 2015 to 77 in 2019. Founders who never closed a round contacted almost as many investors (70 on average) but only averaged 15 meetings.

The gap wasn't how many people they emailed but how many of those turned into an actual conversation.

And while that study is obviously from a different era, and applies to startups across multiple sectors, not just biotech, I find that these numbers are reflective of what we’re seeing today across life sciences.

Revisiting the experiment protocol

Here is another way to look at this - if successful seed raises commonly involve dozens of investor meetings, and your entire starting universe contains only 40-50 names, the math is already working against you, long before you account for the things that always happen along the way: non-response, poor fit, fund conflicts, inactive funds, and ordinary passes.

You can think of this as designing a successful experiment protocol: if you needed 40 measurable data points and designed a study with exactly 40 subjects and no allowance for dropout, contamination, or a failed assay, no reviewer would sign off on it. You'd build in a buffer, because you already know some fraction of your sample won't make it to the readout.

Your investor list deserves the same discipline.

Check your investor list arithmetic

Say about a third of your list has some kind of warm path in, while the other two-thirds will require cold outreach. In my experience, warm outreach might turn into a meeting 15–20% of the time, while cold outreach is often closer to 2–5%.

Run that against a list of 45 investors and you may end up with 5-8 actual meetings after all the non-responses and passes. That’s a reasonable first wave, but you’re still well short of the number of investor conversations that often happen before a term sheet.

Which is why I wouldn’t think of 45 names as your finished investor list. Think of them as the first wave. As that group gets smaller, you should already be sourcing the next one.

INVESTOR SOURCING

Five angles to expand your investor list

The same search will keep giving you the same names

Most founders search for investors along one or two dimensions: sector and stage. That’s a good place to start, but it tends to produce the same familiar names.

Once you start searching from a few different angles, the universe gets much bigger without requiring you to loosen your criteria.

1. Follow the syndicate

When a company announces a financing, most of the attention goes to the lead investor. I would look at everyone else around the table too.

A $4M seed round might include several investors, and some of the smaller participants may never show up in a typical search. They may be micro-VCs, family offices, strategic investors, or smaller funds that don’t have much of a public profile.

Find ten recent financings for companies similar to yours and write down every investor in the round. Company press releases are usually a good place to start. Then look at the other deals those investors have done.

One financing can lead you to another, and pretty quickly you’re following a trail that looks very different from a “top biotech VCs” list.

2. Search by modality, not only indication

If you’re developing a protein degrader in oncology, don’t limit your search to investors who say they invest in oncology.

Look at who has backed other protein degradation companies, including ones working in completely different indications. Those investors have already spent time getting comfortable with the modality, the development path, and many of the risks that come with it.

This can be especially useful at the earliest stages, when an investor’s ability to understand the underlying technology may matter as much as whether they’ve invested in your exact disease area before.

Start with eight to ten companies that share your modality, platform type, or technical approach and look at who backed them in their earliest rounds.

3. Look closer to home, and outside the obvious hubs

Founders understandably spend a lot of time looking at Boston, the Bay Area, and San Diego. But there are plenty of smaller life science ecosystems with their own investors, angel groups, university funds, and economic development programs.

I’d start with your own region. Look at local angel groups, university-affiliated funds, state programs, and investors backing companies coming out of nearby research institutions.

Then do the same exercise in one or two other ecosystems that make sense for your company. Medtech founders, for example, might spend some time looking around the Twin Cities. Depending on your sector, the Research Triangle, Philadelphia, Houston, Toronto, and other regional hubs may also turn up investors you wouldn’t find through a national biotech search.

4. Follow the people, not just the firms

This one is easy to miss because most investor research starts at the firm level.

Go back to some of the financings you think are particularly relevant to your company and figure out which partner actually led the investment, and see where that individual is today.

Partners move firms. Some leave to start their own funds while others change what they invest in.

That history can also give you a much better reason to reach out. “I saw that you led the seed investment in X” is a much stronger starting point than a generic “I saw your firm invests in biotech.”

5. Don’t overlook mission-driven capital

For companies tied to a specific disease area, I would also look at disease foundations, patient organizations, and condition-specific funds.

Some of these organizations make direct investments and others may have translational funding programs, venture arms, or milestone-based awards. And because their mandate is tied to a particular patient population, they may look at opportunities through a different lens than a traditional VC.

This won’t be relevant to everyone. If you’re building a broad platform without a clear disease anchor, there may not be much here. But if you’re working in rare disease or another area with a well-organized patient community, it’s worth checking the major organizations in your space and seeing how they deploy capital.

And a bonus category: the investors themselves

I touched on this in a recent newsletter, but it’s worth highlighting here - the highest leverage habit you can develop as a founder, is always ending each conversation with: “is there anyone you’d recommend I can speak to?”

Especially when someone passes, ask who else they think you should be talking to. You won’t always get a useful answer, but over the course of dozens of conversations, the referrals compound. Some of the best names on your list may ultimately come from investors who never had any intention of writing you a check.

YOUR ACTION PLAN

How to keep your pipeline full

Investor sourcing doesn’t stop when outreach starts

Last week I wrote about how every investor list has a half-life. That’s even more important once you start actively fundraising.

Investors leave firms, funds slow down or stop making new investments and portfolio conflicts appear. New funds close and start writing checks.

And every week you’re reaching out, names are coming off your active list because they took a meeting, passed, or simply never responded.

The world is always in flux and your list should be as well.

Here’s what I’d do this week to make sure your investor list doesn’t go stale while you’re in meetings:

1. Start with what you actually have

Count the investors you’re genuinely prepared to contact, not just the names you’ve added to your tracker. Then highlight funds where you feel you may have a warm path. Based on the numbers we walked through above, roughly how many meetings could that list realistically produce?

2. Pick one of the five angles (but don’t spend hours on it)

Don’t try to run all five at once. Choose the one that’s most relevant to your company and see where it takes you. You can come back to the others later.

3. Keep enough context with every name

At minimum, record the firm, the person you want to reach, where you found them, when you added them, and one sentence on why they’re relevant. Otherwise, a month from now you’ll find yourself researching the same investors all over again.

4. Give yourself a weekly sourcing cadence

Don’t wait until the pipeline starts looking empty to go searching again. Decide how many new, qualified names you want to add each week and keep doing it for as long as you’re raising. The exact number matters less than keeping the pipeline moving.

BONUS RESOURCES

Two prompts to jumpstart the work

If you have access to an AI tool with live web search, here are two prompts built for the first and fourth axes above.

The syndicate mapper

❝

I'm researching investors in [your modality/indication] at the [pre-seed/seed] stage. Search for the 8-10 most recent announced financings (last 12-18 months) for companies working in [modality/indication], similar to [1-2 example companies]. For each financing, list: company name, round size, date, and every investor named in the announcement or press release - not just the lead. Group any investors that appear across multiple rounds. Cite the source for each financing you find.

The partner tracker

❝

In [year], [Partner Name] led the [seed/Series A] round for [Company Name] while at [Fund Name]. Search for their current role - are they still at [Fund Name], have they moved to a new fund, or are they running their own fund now? Include the source and date of the most recent information you find.

One caveat: As always with AI, treat both outputs as a starting point, not a source of truth. Verify every name against the actual press release, portfolio page, public filings and general sanity check before you add the fund to your list or draft an email.

THAT’S A WRAP

Don’t stop at the first 40

Last week, I asked you to make your investor list shorter and more honest. This week, the goal is to make sure it’s big enough to survive a real fundraise.

If you reached out to 40-50 names and haven’t gotten much traction, that can be genuine market feedback. Your pitch deck or outreach may need some fine-tuning, or maybe you’re targeting the wrong investors. But a handful of meetings isn’t enough to tell you which of those is true.

So before you start rewriting the deck or questioning the science, widen the funnel and give yourself enough conversations to find out.

And if you try one of the five angles above, hit reply and let me know what works. I’m always collecting intel on what’s actually working for founders right now, so I can share it back with this community.

Think of it as intel for biotech founders, by biotech founders 🧬💪

Until next week!

- Vadim

PS: Speaking of intel🕵🏻‍♂️ … I've been working on something behind the scenes to help life science founders build better-qualified investor lists and run the fundraising process, and I’m considering opening up free beta access to a select few founders later this month.

If that sounds like it may be helpful, fill out the short survey below about your fundraising experience, and leave your email. Takes 2-3 min and you’ll be the first in line. Also, I’ll be super grateful for your perspective 🙂

When you’re ready, here’s how I can help:

Pitch Deck Audit - a second pair of eyes on your deck before you get in front of investors. I'll go through it the way an investor would and tell you what's landing, what isn't, and what questions you'll get asked. You get slide-by-slide feedback, a custom list of investors, and we spend an hour going through everything live.

Book a strategy call - sometimes it just helps to think out loud with someone who's been on the other side of the table. If that sounds useful, fill out the form below and let’s chat!